重组人类促红细胞生成素治疗新生儿高胆红素血症后贫血临床研究

目的 :探讨使用重组人类促红细胞生成素 (rh Epo)治疗新生儿溶血性高胆红素血症后贫血的可行性、有效性及安全性。方法 :对生后 2～ 5 d临床诊断足月新生儿 G- 6 PD缺陷症或 ABO溶血高胆红素血症随机分为两组。行黄疸治疗待肉眼黄疸消退后 ,治疗组 18例皮下注射 rh Epo2 0 0μ /kg/次 ,3d1次 ,共 6次。结果 :开始使用 rh Epo后第8～ 9w,治疗组与对照组 Hb、Hct、Ret等比较已呈显著差异 (P<0 .0 0 0 1)。在治疗期间血清铁蛋白尚在正常值范围。结论 :早期使用 rh Epo积极干预新生儿溶血性高胆红素血症后贫血 ,是可行、安全及有效的。同时进行正常的母乳喂养可不需额外添加铁剂。

Clinic research of recombinant human erythropoietin in the treatment of anemia after neonatal hyperbilirubinemia

Objective: To assess the feasibility, efficacy and safety of recombinant human erythropoietin(rhEPO) used in the treatment of neonatal anemia after hemolytic hyperbilirubinemia. Methods: 38 term infants 2-5 days old with the diagnosis of G-6PD defect disease or ABO hemolytic disease with hyperbilirubinemia were divided into two groups. After macroscopic jaundice fade with treatment, 18 cases in treated group received subcutaneous rhEPO 200 U/(kg.t), once every 3 days, total 6 times. Results: After 8-9 weeks use of rhEPO, there were significant differences between treatment group and control group on Hb, Hct, Ret, et al ( P <0.0001). And during the treatment serum feeritin was still in the range of normal level. Conclusion: To use rhEPO in the forepart to intervene neonatal anemia after hemolytic hyperbilirubinemia is feasible, safe and effective today while the prepotency policy is performing and the risk of the blood preparation is noticed more and more. Chalybeate need not be extra added for those who are fed with breast milk.